BWBo Wu

Bo Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bo Wu has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Dingyun Song

    Senior Department of Pulmonary and Critical Care Medicine, the Eighth Medical Center of Chinese PLA General Hospital

    2 shared publications
  • Hang Yang

    Nanjing Med Univ, Wuxi Peoples Hosp, Lung Transplant Ctr, Wuxi, Peoples R China

    2 shared publications
  • Jingyu Chen

    Department of Lung Transplantation, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China

    2 shared publications
  • Junjie Du

    Senior Department of Pulmonary and Critical Care Medicine, the Eighth Medical Center of Chinese PLA General Hospital

    2 shared publications
  • Keruo Wang

    Department of Urology, Tianjin Institute of Urology, the Second Hospital of Tianjin Medical University

    2 shared publications
  • Licheng Song

    Senior Department of Pulmonary and Critical Care Medicine, the Eighth Medical Center of Chinese PLA General Hospital

    2 shared publications

Latest Publications

  • Open Access

    B cell-mediated immune reconstitution after lung transplantation: mechanisms, interventions, and prognostic evaluation

    by Yaru Liu, Licheng Song, Ruofan Su, Keruo Wang, Dingyun Song, Yi Yang, Junjie Du, Bo Wu, Lixin Xie

    Lung transplantation remains a life-saving option for patients with end-stage lung disease, yet long-term outcomes remain limited by chronic rejection and infection. Although T cells have historically been the focus of transplant immunology, B cells are now recognized as critical regulators of immune responses through the production of antibodies, antigen presentation, and cytokine secretion. These functions contribute to both protective immunity and antibody-mediated rejection (AMR), particularly in the form of donor-specific antibodies (DSAs), which drive chronic lung allograft dysfunction (CLAD). B cell dysregulation can result from ischemia-reperfusion injury (IRI), infection, and immunosuppressive agents such as tacrolimus (TAC), with distinct effects emerging across perioperative and late post-transplant phases. Advances in single-cell RNA sequencing and B cell receptor (BCR) repertoire profiling have enabled precise characterization of B cell dynamics, offering new opportunities for stratified immune monitoring and risk prediction. This review summarizes B cell biology in lung transplantation, outlines stage-specific perturbations, and explores how multi-omics technologies may support personalized immunomodulation and prognostic assessment.

  • Open Access

    Multi-omics characterises early immune divergence associated with infection-related deterioration after lung transplantation

    by Yaru Liu, Licheng Song, Yi Yang, Jia Liu, Wenjing Guo, Peng Sun, Keruo Wang, Ruofan Su, Dingyun Song, Junjie Du, et al.

    Early adverse outcomes after lung transplantation often manifest as infection-associated clinical deterioration. Such events are closely intertwined with d

  • Open Access

    Impact of donor lung bacteria detected by rapid on-site evaluation on early post-transplant outcomes in lung transplant recipients

    by Tianyang Liu, Yunxiang Zhang, Hang Yang, Xiaoshan Li, Hongmei Wang, Li Fan, Dong Wei, Bo Wu

  • Open Access

    Pulmonary bacterial infection after lung transplantation: risk factors and impact on short-term mortality

    by Rong Gao, Wenjing Wang, Ting Qian, Xiaoshan Li, Hang Yang, Tianyang Liu, Huaqing Yu, Lin Man, Min Xiong, Jingyu Chen, et al.


  • Open Access

    Analysis on the change of gut microbiota and metabolome in lung transplant patients

    by Zhichao Hou, Tangjuan Zhang, Zheng Ding, Ting Qian, Peng Wang, Bo Wu, Xue Pan, Xiangnan Li

    Previous studies have shown that the gut microbiota and its metabolites are associated with the success of organ transplantation. However, the specific changes in the gut microbiota of lung transplant patients remain unclear. Hence, this study aimed to elucidate the interplay between the gut microbiota, metabolome, and lung transplantation outcomes. Using 16S metagenomics sequencing and untargeted metabolic profiling, we conducted a comprehensive analysis of gut microbial and metabolic alterations in lung transplant recipients relative to non-transplant group. Our findings revealed the predominance of Enterococcus and Streptococcus genera within the lung transplant cohort, accompanied by the significant reduction in Bacteroides , Epulopiscium , Faecalibacterium , and Prevotella abundance. In addition, a significant reduction in ATRA (all-trans retinoic acid) levels and suppression of IgA production were observed in lung transplant recipients, which were found to be closely associated with the Enterococcus genus. It was speculated that the association might have implications for the prognosis of lung transplant patients. Notably, the differences in gut microbial composition and metabolomic profiles between successful transplant recipients and those experiencing chronic rejection were not statistically significant. These novel insights shed light on the putative implications of the gut microbiota and metabolome in shaping lung transplantation outcomes, and provide a foundation for future investigations and targeted therapeutic interventions. IMPORTANCE: This study has profound implications for lung transplantation as it uncovers the important role of gut microbiota and metabolome in shaping transplantation outcomes. The identification of dominant bacterial genera, such as Enterococcus and Streptococcus , within the lung transplant cohort, along with the significant decrease in Bacteroides , Epulopiscium , Faecalibacterium , and Prevotella abundance, reveals potential microbial imbalances associated with lung transplantation. In addition, a significant reduction in ATRA (all-trans retinoic acid) levels and suppression of IgA production were observed in lung transplant recipients, which were found to be closely associated with the Enterococcus genus. It was speculated that the association might have implications for the prognosis of lung transplant patients. These findings hold immense clinical significance as they lay the groundwork for future research and targeted therapeutic interventions. Understanding the impact of the gut microbiota and metabolome on lung transplantation outcomes offers promising avenues for improving transplantation patient prognosis.